Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue (2012 - 2019)
Enanta Pharmaceuticals (ENTA) reported Non-Current Deffered Revenue of $900000.0 for Q3 2019, up 51.77% on a YoY basis from $593000.0 in Q3 2018, and down 2.49% quarter-over-quarter from $923000.0 in Q2 2019.
Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue (2012 - 2019) Analysis & Trends
Enanta Pharmaceuticals has reported Non-Current Deffered Revenue for 8 years, with the latest figure at $900000.0 in Q3 2019.
- For the quarter ending Q3 2019, Non-Current Deffered Revenue rose 51.77% year-over-year to $900000.0; the trailing twelve-month figure through Sep 2019 stood at $900000.0 (up 51.77% YoY), and the FY2019 full-year result was $900000.0, up 51.77% from the prior year.
- Non-Current Deffered Revenue for Q3 2019 stood at $900000.0, down from $923000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $923000.0 in Q2 2019, with the low at $161000.0 in Q1 2015.
- Historically, Non-Current Deffered Revenue has averaged $650789.5 across 5 years, with a median of $674000.0 in 2018.
- Annual changes were most pronounced in 2015 — Non-Current Deffered Revenue jumped 322.22% — and 2018, when it retreated 14.06%.
- Enanta Pharmaceuticals' Non-Current Deffered Revenue stood at $646000.0 in 2015, then rose by 8.51% to $701000.0 in 2016, then retreated by 6.7% to $654000.0 in 2017, then climbed by 3.06% to $674000.0 in 2018, then soared by 33.53% to $900000.0 in 2019.
- The last three Non-Current Deffered Revenue figures came in at $900000.0 (Q3 2019), $923000.0 (Q2 2019), and $842000.0 (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 900,000.00 |
| Jun 30, 2019 | 923,000.00 |
| Mar 31, 2019 | 842,000.00 |
| Dec 31, 2018 | 674,000.00 |
| Sep 30, 2018 | 593,000.00 |
| Jun 30, 2018 | 611,000.00 |
| Mar 31, 2018 | 632,000.00 |
| Dec 31, 2017 | 654,000.00 |
| Sep 30, 2017 | 676,000.00 |
| Jun 30, 2017 | 711,000.00 |
| Mar 31, 2017 | 706,000.00 |
| Dec 31, 2016 | 701,000.00 |
| Sep 30, 2016 | 696,000.00 |
| Jun 30, 2016 | 682,000.00 |
| Mar 31, 2016 | 664,000.00 |
| Dec 31, 2015 | 646,000.00 |
| Sep 30, 2015 | 628,000.00 |
| Jun 30, 2015 | 265,000.00 |
| Mar 31, 2015 | 161,000.00 |
| Dec 31, 2014 | 153,000.00 |